SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Autologous, TCR, Topics

March 23, 2023

Strategic Combination of TCR2 Tx and Adaptimmune; Upcoming Clinical Updates for Gavo-cel and TC-510; TCR2 Tx Q4 2022 Earnings Summary

Here is a brief preview of this blast: On Thursday, March 23, 2023, TCR2 Tx released its Q4 2022 financial results and corporate updates (press release) highlighting the agreement with Adaptimmune for merging into a preeminent cell therapy company focused on treating solid tumors announced on March 6, 2023. Additionally, management reported upcoming clinical updates for gavo-cel (autologous MSLN TRuC-T) and TC-510 (autologous MSLN TRuC-T with PD-1:CD28 switch). Below, Celltelligence provides insights on the benefits of TCR2 Tx’s merger with Adaptimmune, while discussing the company’s pipeline reprioritization.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.